A
Angela Dispenzieri
Researcher at Mayo Clinic
Publications - 1212
Citations - 72269
Angela Dispenzieri is an academic researcher from Mayo Clinic. The author has contributed to research in topics: Multiple myeloma & Amyloidosis. The author has an hindex of 117, co-authored 1107 publications receiving 60367 citations. Previous affiliations of Angela Dispenzieri include University of Rochester & Kyungpook National University Hospital.
Papers
More filters
Journal ArticleDOI
Phase 2 Trial of Ixazomib, Lenalidomide, Dexamethasone and Daratumumab in Patients with Newly Diagnosed Multiple Myeloma
Shaji Kumar,Prashant Kapoor,Betsy LaPlant,Eli Muchtar,Francis K. Buadi,Wilson I. Gonsalves,David Dingli,Ronald S. Go,Rahma Warsame,Taxiarchis Kourelis,John A. Lust,Martha Q. Lacy,Angela Dispenzieri,Suzanne R. Hayman,Yi Hwa,Amie Fonder,Miriam Hobbs,Nelson Leung,S. Vincent Rajkumar,Morie A. Gertz,Eric G. Wolfe +20 more
TL;DR: The early results from the use of IRd-Dara in newly diagnosed myeloma suggests excellent efficacy with rapid responses that deepen quickly over the initial cycles of therapy.
Journal ArticleDOI
Rituximab-based maintenance therapy in Waldenström macroglobulinemia: A case control study.
Saurabh Zanwar,Jithma P. Abeykoon,Morie A. Gertz,Shaji Kumar,David J. Inwards,Luis F. Porrata,Carrie A. Thompson,Thomas E. Witzig,Thomas M. Habermann,Ronald S. Go,Martha Q. Lacy,S. Vincent Rajkumar,Angela Dispenzieri,Francis K. Buadi,Wilson I. Gonsalves,Nelson Leung,Suzanne R. Hayman,Robert A. Kyle,Stephen M. Ansell,Prashant Kapoor +19 more
TL;DR: Waldenstrom macroglobulinemia is a rare indolent lymphoma commonly treated with rituximab (R)-based therapy and the use of ritUXimab maintenance (mR) in WM is controversial.
Journal ArticleDOI
Treatment trade-offs in myeloma: a survey of consecutive patients about contemporary maintenance strategies
Brian L. Burnette,Angela Dispenzieri,Shaji Kumar,Ann M. Harris,Jeff A. Sloan,Jon C. Tilburt,Robert A. Kyle,S. Vincent Rajkumar +7 more
TL;DR: A systematic survey of patients with multiple myeloma regarding what constitutes a meaningful benefit that would make burdens of maintenance treatments (toxicity and cost) acceptable.
Book ChapterDOI
Multiple Myeloma and Related Disorders
TL;DR: An array of related plasma cell disorders need to be distinguished from myeloma, including monoclonal gammopathy of undetermined significance, smoldering multiple myelomas, Waldenstrom macroglobulinemia, solitary plasmacytoma, and AL amyloidosis.
Journal ArticleDOI
Correlation between urine ACR and 24-h proteinuria in a real-world cohort of systemic AL amyloidosis patients
Alissa Visram,Alissa Visram,Abdullah S. Al Saleh,Abdullah S. Al Saleh,Harsh Parmar,Jennifer S. McDonald,John C. Lieske,Iuliana Vaxman,Iuliana Vaxman,Iuliana Vaxman,Eli Muchtar,Miriam Hobbs,Amie Fonder,Yi L. Hwa,Francis K. Buadi,David Dingli,Martha Q. Lacy,Angela Dispenzieri,Prashant Kapoor,Suzanne R. Hayman,Rahma Warsame,Taxiarchis Kourelis,Mustaqeem A. Siddiqui,Wilson I. Gonsalves,John A. Lust,Robert A. Kyle,S. Vincent Rajkumar,Morie A. Gertz,Shaji Kumar,Nelson Leung +29 more
TL;DR: The uACR is a reliable and convenient method for ruling out proteinuria >500 mg per day, prognosticating renal outcomes, and assessing renal response to therapy.